For more than 4 decades, pediatricians have sought the best practices for effectively managing well-appearing young febrile infants. In 2021, the American Academy of Pediatrics released a clinical practice guideline for the management of well-appearing febrile infants aged 8 to 60 days. The guideline incorporates advancements in testing, such as biomarkers and diagnostic testing in the setting of changing epidemiology, to help risk stratify infants in the newly formed group age 22 to 28 days as well as the group age 29 to 60 days. The new guideline uses inflammatory markers (procalcitonin, C-reactive protein, absolute neutrophil count, and a temperature >38.4°C) to identify infants at low risk for invasive bacterial infection who can potentially avoid the invasive procedures of lumbar puncture, hospitalization, and broad-spectrum antimicrobials. Because of continued ambiguity, incorporating shared decision-making with families in the care of these infants will be important, as will ongoing clinical research to better inform future practice. [Pediatr Ann. 2024;53(6):e202-e207.].

中文翻译：

---

安全地减少发热婴儿的治疗：根据 2021 年美国儿科学会临床实践指南审查管理。


四十多年来，儿科医生一直在寻找有效管理外观良好的小发热婴儿的最佳实践。 2021年，美国儿科学会发布了管理8至60天表现良好的发热婴儿的临床实践指南。该指南融合了检测方面的进步，例如在流行病学变化的背景下进行生物标志物和诊断检测，以帮助对新形成的 22 至 28 天年龄组以及 29 至 60 天年龄组中的婴儿进行风险分层。新指南使用炎症标志物（降钙素原、C反应蛋白、中性粒细胞绝对计数和体温>38.4°C）来识别侵袭性细菌感染低风险的婴儿，这些婴儿可以避免腰椎穿刺、住院和住院等侵入性操作。广谱抗菌剂。由于持续的模糊性，在照顾这些婴儿时与家庭共同决策将很重要，正在进行的临床研究也将更好地为未来的实践提供信息。 [小儿安。 2024；53(6):e202-e207。]。